ERC Einstein-Rockefeller-CUNY Center for AIDS research

ERC 爱因斯坦-洛克菲勒-纽约市立大学艾滋病研究中心

• 批准号: 10605256
• 负责人: HARRIS GOLDSTEIN
• 金额: $ 295.91万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-01 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10605256
• 关键词: AIDS prevention; Acceleration; Acquired Immunodeficiency Syndrome; Adherence; Affinity; Area; Award; Basic Science; Behavioral; Behavioral Research; Behavioral Sciences; Biological Markers; Cities; Clinical; Clinical Research; Clinical Sciences; Collaborations; Communities; Community Health; Country; County; Data; Development; Diagnosis; Eligibility Determination; Epidemic; Epidemiology; Failure; Financial Support; Funding; Future; Goals; Grant; HIV; HIV Infections; HIV diagnosis; HIV/AIDS; Health; Health system; Immunologic Adjuvants; Implant; Improve Access; Infection; Inflammatory; Infrastructure; Institution; Interdisciplinary Study; Investments; Knowledge; Lead; Leadership; Link; Location; Logistics; Medicine; Mental Health; Mental disorders; Mentors; Modality; National Institute of Mental Health; New York; New York City; Outcome; Paper; Pathogenesis; Patients; Persons; Play; Population; Prevention; Process; Productivity; Prophylactic treatment; Public Health; Public Health Schools; Publications; Publishing; Research; Research Personnel; Research Priority; Resources; Role; Services; Site; Strategic Planning; Technology; Translating; Translational Research; United States; United States National Institutes of Health; Universities; Vacuum; Viral; Viremia; Vision; antiretroviral therapy; base; behavioral study; catalyst; chimeric antigen receptor T cells; clinical center; college; economic disparity; epidemiology study; forging; implementation research; implementation science; implementation strategy; improved; innovation; member; neurochemistry; neutralizing antibody; next generation; novel; novel therapeutics; pandemic disease; pre-exposure prophylaxis; prevent; preventive intervention; programs; recruit; response; scale up; social disparities; success; synergism; therapy adherence; transmission process; uptake; working group

PROJECT SUMMARY ERC-CFAR: OVERALL As the HIV research community and public health systems implement the vision of Ending the HIV Epidemic (EHE), Centers for AIDS Research (CFAR) play a crucial role leading the trans-institutional and interdisciplinary research efforts needed to achieve this goal. We successfully filled a vacuum in New York City, a continuing epicenter of HIV infection previously lacking a CFAR, by creating the Einstein-Rockefeller-CUNY CFAR (ERC- CFAR). The ERC-CFAR brings together and synergizes the complementary expertise and resources of researchers from a strong basic and clinical research institution linked to a health system which treats >6,200 people with HIV, the Albert Einstein College of Medicine (Einstein); a globally pre-eminent basic science institution, Rockefeller University (Rockefeller); and a strong public health/implementation science institution, CUNY School of Public Health/Hunter College (CUNY), while establishing linkages to the NYC Department of Health and Mental Hygiene. Our vision is for the ERC-CFAR to serve as a catalyst to create innovation and contribute to EHE by breaking down institutional and disciplinary silos in our complementary basic, translational, clinical, epidemiologic, behavioral, and implementation research programs to accelerate development of new therapies, assess and overcome barriers to acceptability, uptake, and adherence, and prevent and cure HIV infections. The success of the ERC-CFAR Cores, SWGs, and infrastructure in amplifying the research productivity of our three institutions is illustrated by a >30% increase in our OAR FRB from ~$34 million in FY15 to ~$44.6 million in FY20 and the publication of >1,250 papers by ERC-CFAR investigators. Our ESIs obtained ~$20 million of external grant funding, including ~$7.5 million in NIH grants catalyzed by ~$500K we awarded for 14 pilot grants, a >16-fold return on investment. We also integrated the concerns of our community members, including PWH, into our strategic planning process by organizing a novel, highly trans-institutional and interdisciplinary Scientific Working Group (SWG), with greater than 30 members focused on our community’s priority research area, HIV and Mental Health. In this renewal, we propose to build on our accomplishments to further catalyze research to end the epidemic through these Specific Aims: 1) To assemble transinstitutional, interdisciplinary, community-inclusive ERC-CFAR research teams to develop and implement new strategies to reduce HIV transmission, improve prevention and treatment, promote sustained viral suppression, and eradicate HIV reservoirs; 2) To increase the impact of our research through the cutting-edge services of our Biomarkers and Advanced Technologies Core, Behavioral and Implementation Science Core, and Clinical and Translational Science Core; 3) To mentor the next generation of HIV investigators, recruit established non-HIV investigators into HIV research, and forge new collaborations across Einstein, Rockefeller, and CUNY, other NIH-funded centers, regional academic centers, our public health departments, and community partners to support an innovative EHE agenda through the Developmental Core and current HIV & Mental Health and future SWGs.

项目概要 ERC-CFAR：总体 随着艾滋病毒研究界和公共卫生系统实施终结艾滋病毒流行的愿景 (EHE)、艾滋病研究中心 (CFAR) 在领导跨机构和跨学科研究中发挥着至关重要的作用 实现这一目标所需的研究努力成功地填补了纽约市的空白，这是一项持续的工作。 通过创建爱因斯坦-洛克菲勒-纽约市立大学 CFAR (ERC- CFAR）汇集并协同了互补的专业知识和资源。 来自强大的基础和临床研究机构的研究人员，该机构与治疗超过 6,200 名患者的卫生系统相关 艾滋病毒感染者，阿尔伯特·爱因斯坦医学院（爱因斯坦）； 机构，洛克菲勒大学（洛克菲勒）；以及强大的公共卫生/实施科学机构， 纽约市立大学公共卫生学院/亨特学院 (CUNY)，同时与纽约市卫生局建立联系 我们的愿景是让 ERC-CFAR 成为创造创新和发展的催化剂。 通过打破我们互补的基础、转化、 临床、流行病学、行为和实施研究项目，以加速新药物的开发 疗法，评估和克服可接受性、吸收和依从性方面的障碍，并预防和治愈艾滋病毒 ERC-CFAR 核心、SWG 和基础设施在扩大研究方面取得了成功。 我们三个机构的生产率从 2015 财年的约 3400 万美元的 OAR FRB 增长了超过 30% 看出 我们的 ERC-CFAR 研究人员获得了 2020 财年约 4,460 万美元的资金，并发表了超过 1,250 篇论文。 约 2000 万美元的外部赠款资金，其中包括由我们授予的约 50 万美元推动的约 750 万美元的 NIH 赠款 14 项试点资助，投资回报率超过 16 倍。我们还整合了社区成员的担忧， 通过组织一个新颖的、高度跨机构的和 跨学科科学工作组 (SWG)，拥有超过 30 名成员，专注于我们社区的 优先研究领域，艾滋病毒和心理健康 在这次更新中，我们建议在我们的成就的基础上再接再厉。 通过以下具体目标进一步促进研究以终结这一流行病：1) 汇集跨机构、 跨学科、社区包容的 ERC-CFAR 研究团队制定和实施新战略 减少艾滋病毒传播，改善预防和治疗，促进持续病毒抑制，并根除艾滋病毒 HIV 储存库；2) 通过我们的生物标记物的尖端服务来提高我们研究的影响力 和先进技术核心、行为和实施科学核心、临床和转化 科学核心；3) 指导下一代艾滋病毒研究人员，招募非艾滋病毒研究人员 进入艾滋病毒研究，并与爱因斯坦、洛克菲勒和纽约市立大学以及其他 NIH 资助的机构建立新的合作 中心、区域学术中心、我们的公共卫生部门和社区合作伙伴，以支持 通过发展核心、当前的艾滋病毒和心理健康以及未来的 SWG 进行创新的 EHE 议程。